SyntheX is a biotechnology and pharmaceutical company that was founded by Charly Chahwan and Maria Soloveychik in 2016, and is headquartered in San Francisco, California. SyntheX uses a proprietary drug design approach and in-vivo screening platform, ToRPPIDO, to identify compounds that disrupt protein-protein interactions (PPIs). Their lead stabilized peptide inhibitor drugs, STX101 and STX105, block PPIs within the BRCA2 pathway, mimicking a BRCA2 mutation.
On April 20, 2017 SyntheX closed their seed funding round with $6.2 million in seed round funding from Morgan Noble, SOSV, Oriza Ventures, and 8VC.
Documentaries, videos and podcasts